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ABSTRACT
The implementation of personalised medicine in childhood cancers has been 
limited by a lack of clinically validated multi-target sequencing approaches specific 
for paediatric solid tumours. In order to support innovative clinical trials in high-risk 
patients with unmet need, we have developed a clinically relevant targeted sequencing 
panel spanning 311 kb and comprising 78 genes involved in childhood cancers. A total 
of 132 samples were used for the validation of the panel, including Horizon Discovery 
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cell blends (n=4), cell lines (n=15), formalin-fixed paraffin embedded (FFPE, n=83) 
and fresh frozen tissue (FF, n=30) patient samples. Cell blends containing known 
single nucleotide variants (SNVs, n=528) and small insertion-deletions (indels 
n=108) were used to define panel sensitivities of ≥98% for SNVs and ≥83% for 
indels [95% CI] and panel specificity of ≥98% [95% CI] for SNVs. FFPE samples 
performed comparably to FF samples (n=15 paired). Of 95 well-characterised genetic 
abnormalities in 33 clinical specimens and 13 cell lines (including SNVs, indels, 
amplifications, rearrangements and chromosome losses), 94 (98.9%) were detected 
by our approach. We have validated a robust and practical methodology to guide 
clinical management of children with solid tumours based on their molecular profiles. 
Our work demonstrates the value of targeted gene sequencing in the development of 
precision medicine strategies in paediatric oncology.
INTRODUCTION
Cancer remains the leading cause of death due 
to disease in children aged >1 year [1]. Cure rates for 
paediatric solid tumours have not substantially improved 
in the past decade with patients having recurrent disease 
performing particularly badly, reflecting the limitations of 
current approaches that employ intensive chemotherapy, 
surgery and radiation [2–4]. In adults, the stratification 
of patients by genetic profiling using high throughput 
sequencing has supported adaptive clinical trials [5, 6], 
and there is an urgent need to translate such opportunities 
to the treatment of childhood disease.
The genomic landscape of paediatric cancer is 
becoming increasingly well-defined leading to the 
conclusion that childhood cancers have in general fewer 
somatic mutations than adults, but that mutations in 
epigenetic regulators occur at a higher incidence [7–
17]. Key recent findings include recurrent mutations 
in the genes encoding histones 3.3 and 3.1 (H3F3A 
and HIST1H3B) as well as the activin A receptor type I 
(ACVR1) that are unique to paediatric high-grade glioma 
(pHGG) and diffuse intrinsic pontine glioma (DIPG) [18–
20]. Similarly, ATRX mutations, TERT rearrangements and 
MYCN amplification define mutually exclusive molecular 
subgroups of neuroblastoma, all of which are associated 
with poor prognosis [21–23]. The newly proposed 
molecular-based medulloblastoma sub-classification 
defines subgroups, each of which potentially requires a 
tailored therapeutic strategy [7, 11, 24].
Despite our improved knowledge of somatic 
alterations in paediatric cancers, precision medicine 
remains unavailable for the majority of patients. For 
example, a small number of early-phase paediatric trials 
are recruiting children whose tumours harbour genetic 
alterations including ALK genomic alterations (mutations, 
amplifications or translocations) that can be treated with 
ALK inhibitors and BRAF V600 mutant tumours that can 
be treated with BRAF or MEK inhibitors.
In addition, there is now an extensive list of 
recurrent genetic alterations with potential diagnostic, 
prognostic or predictive value, and sequential testing 
of single genes using standard methods has become 
unfeasible due to lack of available material and high 
costs. High-throughput sequencing (also known as next 
generation sequencing or NGS) offers a solution to these 
issues. In particular, panel-based NGS assays which 
simultaneously sequence a targeted set of genes with 
recurrent alterations, associated with known clinical 
or biological implications are cheaper, less challenging 
in terms of interpretation and more suited to clinical 
diagnostics than current approaches [25]. Despite this, 
development and validation of high throughput gene 
panel sequencing is challenging. Typically, DNA is 
only available from formalin-fixed, paraffin-embedded 
(FFPE) samples, which yields relatively poor quality 
DNA. DNA extraction and library construction to 
clinical laboratory standards requires optimisation, and 
it is necessary to construct a standardised informatics 
pipeline that identifies and interprets actionable 
mutations. Appropriate and rapid clinical reporting of 
identified variants and incorporation of the results into 
the electronic patient records also need to be considered 
if molecular stratification of childhood cancer is to 
be successfully translated to the clinic [26]. There are 
several examples of validation and implementation 
of targeted sequencing in adult cancer [27–30]. In 
the past two years, several approaches using high-
throughput sequencing have been applied for clinical 
decision-making in children with solid tumours [31–
34], however a clinically validated panel specifically 
targeting recurrent alterations in childhood cancers using 
archival FFPE specimens would significantly assist the 
development of molecular stratification strategies in 
paediatric oncology.
Here we describe the development and validation, 
within an accredited clinical pathology laboratory (CPA 
UK), of a paediatric solid tumour sequencing panel 
for use with either routine FFPE or fresh frozen (FF) 
samples. As part of the validation, we established overall 
performance, sensitivity, specificity, repeatability, 
reproducibility, accuracy and limit of detection, 
following guidelines previously described for validation 
of genetic tests [35].
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RESULTS
Selection of panel content
The panel design covers a total of 78 genes (Table 1), 
either recurrently altered in paediatric cancers or clinically 
actionable in adult cancers and with potential application in 
childhood solid tumours. The genes were selected in wide-
collaboration with national experts in paediatric oncology 
patient care covering all areas of paediatric solid tumours 
(glioma, medulloblastoma, bone sarcomas, soft tissue 
sarcomas, renal tumours and neuroblastoma among others). 
Targets were chosen by consensus based on most clinically 
relevant aberrations including: i) predictive biomarker (level 
1), prognostic biomarker (level 2), diagnostic biomarker (3) 
potentially targetable biomarkers with inhibitors available 
or under development (level 4), known germline or high 
risk single nucleotide polymorphism (level 5) or unclear 
significance, research only (level 6). Factors influencing the 
choice of targets included: childhood tumour type where 
alterations have been reported, molecules targeting these 
genes and clinical trials available for children with solid 
tumours (Supplementary Table 1A). A library of customized 
biotinylated DNA probes was designed to capture a total 
of ~311(kilobase) kb for the detection of single nucleotide 
variants (SNVs), short insertion-deletions (indels), 
copy number variations and structural rearrangements 
(Supplementary Table 1B). Exons were padded with 5 base 
pairs (bp) of intronic sequence to increase exon depth and for 
detection of splice-site variants.
Panel validation
Research use of sequence capture assays has 
become common, but basing clinical care on gene panel 
sequencing results requires confident calling of both 
variant and non-variant sequence, and a full understanding 
of the performance of the assay. Implementation in the 
clinic therefore requires robust validation in an accredited 
laboratory.
To validate the paediatric gene panel, we followed 
the standardised framework for clinical assay validation 
set out by Mattocks et al. [35]. We determined overall 
performance of the panel across the target regions, 
measuring precision, sensitivity and specificity. As 
a standard, we used a set of four Horizon cell blends 
previously characterized by NGS and droplet digital 
PCR (ddPCR) (Supplementary Table 2A and 2B) and 
15 paediatric cell lines with known variants. For further 
validation, we performed capture and sequencing on 83 
FFPE and 30 FF clinical samples (Supplementary Table 3).
Overall performance
Overall, the panel performed well, with over 96% 
of 901 regions of interest achieving specification. Only 
24 (2.7%) regions were classified as underperforming 
across the four cell blends and five FFPE samples, with 
read depth lower than 2 x standard deviation (SD) of the 
mean based on log2 (Supplementary Table 4A and 4B). 22 
of 24 underperforming regions were located within highly 
GC-enriched regions, which are known to be refractory to 
efficient hybridization and/or amplification (Figure 1 and 
Supplementary Table 4C).
Quality and coverage metrics were generated 
across all samples (Supplementary Tables 5 and 6). The 
average total number of reads was 8.8x106 (SD=3.1x106) 
for FFPE and 7.9x106 (SD=3x106) for high molecular 
weight (HMW) samples (FF and cell lines). The 
percentage mapped (96.1±3.9 for FFPE vs 97.3±2.5 for 
high molecular weight samples) and percentage of bases 
from unique reads on target (45.9±3 for FFPE vs 42.7±2.4 
for HMW) was very similar for both FFPE and HMW 
samples. Duplicates were higher in FFPE samples (60.2% 
for FFPE vs 36.1% for HMW). The overall mean depth 
was 698 ± 365 for FFPE vs 899 ± 347 for HMW (Table 2).
Limit of detection
To determine the limit of detection, SNVs present 
in the cell blends at known variant allele frequency (VAF) 
were used. The pipeline detected all 61 SNVs including 
33 SNVs with an expected VAF of 4-5%. 15/17 expected 
indels were detected. Of the two indels not detected, one 
was 18 bp in length at an expected VAF of 4.2%, whilst the 
other was 2 bp at 5% VAF (Figure 2 and Supplementary 
Table 7A). We therefore established a minimum threshold 
of 5% VAF in the analysis pipeline, which allows for 
detection of a heterozygous mutation when >10% 
neoplastic cells are present in the tumour sample.
Assessment of precision
To measure precision, we took advantage of natural 
variants present as intrinsic “background” SNVs and 
indels in the captured regions from the four cell blends. 
Precision was assessed by comparing the alterations 
expected with those detected to obtain within run-
precision (repeatability), and between run-precision data 
(intermediate precision). Variants ≤ 5% in all four blends 
and within poor performing regions were excluded leaving 
a total of 528 SNVs (132 variants in 4 blends) and 108 
indels (27 indels in 4 blends) for analysis. All of the 528 
SNVs and 90 out of 108 (83%) indels were detected 
(Supplementary Table 8).
Repeatability
Pairwise correlation of VAF between runs was 
r2≥0.994 [95%CI:0.991-0.996] for SNVs and r2≥0.785 
[95%CI:0.652-0.919] for indels (Supplementary Figures 1 
and 2) indicating that the panel accurately reproduces data 
from independently prepared samples on the same run.
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Intermediate precision
Pairwise correlation was r2≥0.995 [95%CI:0.993-
0.997] and overall correlation was r2=0.996 [95%CI:0.995-
0.997] for SNV detection. For indels pairwise correlation 
was r2≥0.827 [95%CI: 0.716-0.937] and overall 
correlation was r2≥0.875 [95%CI:0.829-0.921] (Table 3 
and Supplementary Figures 3 and 4) indicating that the 
panel accurately reproduces data from repeat samples on 
different runs.
Assessment of sensitivity and specificity
To determine sensitivity we used the same 
background 528 SNVs and 108 indels, together with the 
known cancer-specific variants (61 SNVs and 17 indels) 
from the four cell blends. SNVs and indels were called 
and their presence was compared to the list of variants 
expected in the capture regions from the cell blends 
(Supplementary Tables 7A and 8). All the SNVs were 
detected, resulting in a sensitivity of ≥98% [95%CI:0.98-
1]. From the 108 background indels, 18 were not detected, 
as were 2 of the cancer-specific indels, obtaining a 
sensitivity of ≥83% [95%CI:0.761-0.897]. True Positive 
(TP) of all SNVs = 589; False-Negative (FN) of all SNVs 
= 0. TPs of all indels = 105; FNs of all indels = 20. The 
undetected indels were manually checked on Integrative 
Genomics Viewer (IGV). We observed that 12 of 20 were 
located +4 bp upstream of the exon (our bed file covers ±5 
bp), four had poor coverage, two fell in highly repetitive 
regions and one was a long indel (18bp).
To determine specificity, we used the cancer-specific 
data from the four cell blends harbouring a total of 61 
true positive and 87 true negative SNVs (Supplementary 
Table 7B). There were insufficient true negatives (n=3) 
to determine specificity for indels. SNVs were called 
and their presence was compared to the list of variants 
expected in the capture regions from the cell blends. 
The specificity of cancer-specific SNVs was ≥98% 
[95%CI:0.946-1]. Positive-Predictive Value (PPV) was 
≥98% [95%CI:0.926-1] and the Negative-Predictive Value 
(NPV) was ≥98% [95%CI:0.946-1].
The range of VAF for the SNVs detected by 
our pipeline, including the background and the cancer 
specific variants (528 + 61 = 589), was 23% at ≥ 50% 
VAF (134/589), 35% at 50-20% of VAF (207/589) and 
42% at < 20% (248/589). The range of VAF for the indels 
detected by our pipeline including the background and 
cancer specific indels (90 + 15 = 105) was 0% at > 50% of 
VAF (0/105), 31% at 50-20% of VAF (33/105) and 69% 
Table 1: Gene panel list including 78 genes recurrently altered in paediatric cancers or clinically actionable
ACVR1 CTNNB1 IL3 PPM1D
AKT1 DDR2 IL6 PTCH1
ALK DDX3X KIT PTEN
AMER1 DICER1 KMT2D PTPN11
APC EGFR KRAS PTPRD
ARID1A ERBB2 LMO1 RB1
ARID1B ERG MAP2K1 RET
ASXL1 ETV6 MAP2K2 ROS1
ATM EWSR1 MDM2 SETD2
ATRX FBXW7 MYCN SMARCA4
BARD1 FGFR1 MYOD1 SMARCB1
BCOR FGFR2 NCOA2 SS18
BRAF FGFR3 NF1 SUFU
CASC15 FGFR4 NRAS TENM3
CDK4 FUS PAX3 TP53
CDK6 H3F3A PAX7 TSC1
CDKN2A HIST1H3B PDGFRA WT1
CDKN2B HIST1H3C PHOX2B ZHX2
CFL1 HRAS PIK3CA  
CHEK2 IDH1 PIK3R1  
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<20% (72/105). The range of VAF for the cancer specific 
variants detected by the NGS panel was in line with the 
manufacturer’s specifications.
Performance and variant detection comparison 
in paired FF-FFPE clinical samples
To assess the performance of the panel on real 
clinical material we compared 15 paired clinical DNA 
samples isolated from both FF and FFPE samples. For 
the FFPE samples, we obtained an average of 93.4% ± 
5.42% and 80.3% ± 20.3% of targeted positions covered 
at depths of ≥ 100x and ≥ 250x respectively. The overall 
mean depth for FFPE was 785 ± 333. Overall percentage 
of bases from unique reads on target for FFPE was 47.6% 
± 2.3%. For FF samples, we obtained an average of 96.6% 
± 0.6% and 90.9% ± 1.9% of targeted positions covered 
at depths of ≥ 100x and ≥ 250x respectively. The overall 
mean depth for FF was 977 ± 142. Overall percentage 
of bases from unique reads on target for FF was 44% ± 
2.2%. As expected, duplicates were substantially lower in 
FF samples (54.5% for FFPE vs 29.9% for FF). Insert size 
for the library pre-capture DNA was 285 bp ± 24 for FFPE 
and 326 bp ± 24 for FF (Table 4).
VAFs found in the paired FF-FFPE samples 
were compared, obtaining an overall correlation of r2 = 
0.983 (95%CI: 0.984-0.985; p<0.0001) (Figure 3 and 
Supplementary Figure 5). A total of 42.3% (5562/13146) 
variants were detected in FF but not in FFPE, of which 
78.1% (4346/5562) had VAF below 5%, with 17.6% 
(982/5562) having VAF between 5-10%. Less than 5% 
variants missed in FFPE samples were present in FF at 
VAF above 10%.
Conversely, a total of 8.2% (1084/13146) variants 
were detected in FFPE but not in FF, of which 50.8% 
(551/1084) had VAF below 5%, with 33.2% (360/1084) 
having VAF between 5-10%, and the remaining 16.0% 
(173/1084) were present in FFPE only at VAF above 
10%.
Detection of known variants in paediatric 
samples
To assess the ability of the panel to detect known 
variants in clinical samples, we performed a variant 
analysis of 41 paediatric samples with 90 known genetic 
abnormalities (30 alterations in 13 cell lines and 60 
alterations in 14 FFPE and 14 FF samples with known 
genetic alterations identified by routine testing): 50 SNVs, 
including mutations in TP53, ALK, CTNNB1, DDX3X, 
SMARCA4, one duplication (BRAF p.Thr599dup), 7 indels 
including DDX3X and TP53, 13 amplifications including 
MYCN and CDK4, and 19 chromosome/gene losses, for 
example chr 9q loss including loss of PTCH1 and TSC1. 
100% of the variants interrogated by the panel were 
successfully detected (Tables 5 and 6 and Supplementary 
Table 9).
Detection of rearrangements
Five sarcoma FFPE samples were included in 
the analysis where translocations had previously been 
detected by RT-qPCR involving EWSR1. Rearrangements 
in EWSR1 were detected in four out of the five FFPE 
samples (80%) leading to fusion genes of EWSR1 with 
partners ATF1 (detected in two samples), FLI1 and 
CREB1 (Supplementary Figure 6). The fusion not detected 
was EWSR1-NR4A3. This is too small a sample to confirm 
validation of the panel for detection of translocations at 
this stage and further work is in progress.
Figure 1: Bar plot showing GC content in the 901 regions captured by the panel. The plot is ordered from low to high GC-
content of each region captured. Red bars highlight the underperforming regions (24/901), mainly located within GC-enriched regions.
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DISCUSSION
Targeted therapies are already the standard of 
care for several molecular subgroups of adult cancers. 
EGFR mutations or ALK rearrangements in lung cancer, 
BRAF V600E mutations in metastatic melanoma and 
breast cancer patients harbouring HER2 amplifications 
are examples of therapeutic biomarkers routinely used 
in the adult population [36–38]. The implementation of 
personalised medicine in paediatric oncology has remained 
challenging partly due to the low incidence of childhood 
cancer, accessibility of drugs and regulatory hurdles [39]. 
Nevertheless, the understanding of genetics in childhood 
cancer over the last decade has improved thanks to 
large sequencing initiatives across the world [31–33]. 
The updated World Health Organization Classification 
(WHO) classification of brain tumours based on molecular 
features is a clear example of the huge impact of applying 
molecular profiling to guide diagnosis and treatment with 
the potential to improve outcomes in childhood cancers 
[40].
We have developed an NGS targeted sequencing 
based diagnostic test to accurately detect clinically 
relevant genomic alterations across 78 cancer genes 
in routine FFPE as well as FF paediatric samples. The 
overall performance of our assay was excellent; from the 
901 regions captured only 24 (<3%) failed the quality 
control metrics mainly as a result of being located in GC-
rich regions, and should be noted for future panel design. 
VAF for known SNVs and indels were very similar in 
within-run and between-run replicates, demonstrating 
that the assay is repeatable and reproducible. SNVs 
were detected at a wide range of VAFs simulating the 
heterogeneity expected in cancer samples including 33 
SNVs with an expected VAF of 4-5%. The detection 
of variants at low VAF is crucial, especially in samples 
with a low neoplastic cell content. Sensitivity was ≥98% 
for SNVs and ≥83% for indels and specificity ≥98% for 
SNVs. False-negative calls were mostly indels at low 
VAF (≤5%) and predominantly occurred at splice sites. 
Variants were analysed in exons and the surrounding 5 
bp, but were not reported by our pipeline if they occurred 
outside ±2 bp of the coding region. This could be solved 
expanding the sequence covered by bed file at intron:exon 
boundaries, but the relevance of these variants remains 
unclear. There is currently no consensus as to the most 
Figure 2: Comparison of known variant allele frequencies by droplet digital PCR (x axis) against variant allele 
frequency obtained by NGS (y axis) for all cancer-specific variants (61 single nucleotide variants, SNVs and 17 
insertion-deletions, indels). Overall correlation was r2=0.969 [95% CI: 0.975-0.990; p<0.0001].
Table 2: Average quality metrics across all samples. Data expressed as means ± standard deviation
 Total reads Percentage of reads mapped
Percentage of 
duplicates
Percentage of 
unique on target Mean depth
FFPE (n=83) 8.8x106±3.1x106 96.1±3.9 60.2±13.7 45.9±3 698±365
FF and cell lines 
(n=49) 7.9x10
6 ±3x106 97.3±2.5 36.1±9.7 42.7±2.4 899±347
Oncotarget112042www.impactjournals.com/oncotarget
appropriate minimum region of interest to cover at 
splice sites for clinical reporting and in many cases the 
biological meaning of these mutations are unknown. The 
latest guidelines recommend calling likely disrupted gene 
function in nonsense, frameshift, canonical ±1 or ±2 splice 
sites, initiation codon, and single exon or multi-exon 
deletion, all of which would be covered with our current 
pipeline [41].
We also compared the performance of paired FFPE-
FF specimens obtaining comparable quality metrics 
between both tissue types, as well as a high overall 
correlation of VAF. This is particularly important as most 
clinical samples routinely available are derived from FFPE 
tissue where nucleic acid quality is generally compromised 
and chemically challenged, leading to DNA degradation 
and potential deamination or oxidation artefacts. The 
discrepancies of the variants observed between FFPE 
and FF were mainly at low VAF, below or at the lower 
limit of detection of our approach. The discrepancies of 
the variants above 10% could be explained by variation 
in neoplastic cell content between FF and FFPE and intra-
tumour heterogeneity leading to sub-clonal alterations. 
Three of the samples with more striking differences 
were brain tumours which are well known as highly 
heterogeneous tumours [42, 43].
We verified the accuracy of our NGS approach in 
cell lines and clinical specimens (FFPE and FF) containing 
known genetic abnormalities previously characterized by 
other methodologies and obtained a high concordance (r2 = 
0.983). The FFPE and FF samples used for the validation 
were a cohort of specimens from several hospitals across 
the world. We obtained reproducible and accurate results 
Table 3: Pairwise correlation of (A) single nucleotide variants (SNVs) and (B) insertion-deletions (indels) for each of 
the 4 cell blends with identical background variants between the two runs
A Samples Correlation Standard Error Lower 95%CI Upper 95%CI
Tru-Q1-HD728-T 0.995 0.001 0.993 0.997
Tru-Q2-HD729-T 0.996 0.001 0.995 0.997
Tru-Q3-HD730-T 0.996 0.001 0.995 0.998
Tru-Q4-HD731-T 0.997 0.001 0.995 0.998
B Samples Correlation Standard Error Lower 95%CI Upper 95%CI
Tru-Q1-HD728-T 0.912 0.03 0.853 0.971
Tru-Q2-HD729-T 0.905 0.032 0.842 0.969
Tru-Q3-HD730-T 0.858 0.047 0.766 0.951
Tru-Q4-HD731-T 0.827 0.057 0.716 0.937
Figure 3: Overall correlation of variant allele frequency (VAFs) found between the 15 formalin-fixed paraffin 
embedded (x axis) and fresh frozen (y axis) paired samples.
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Table 4: Comparison of quality metrics between formalin-fixed paraffin embedded (FFPE) and fresh frozen (FF) 
matched samples (n=15) 
 Total reads Percentage of reads mapped
Percentage of 
duplicates
Percentage of 
unique on target Mean depth
FFPE (n=15) 8.7x107±3.4x106 95.5±2.2 54.5.2±9.2 47.6±2.3 785±333
FF (n=15) 7.7x106 ±1.2x106 98.6±0.7 29.9±6.9 44.2±2.2 977±142
Data expressed as means ± standard deviation.
Table 5: Known variants in paediatric cancer cell lines were compared against capture sequencing from the Cancer 
Cell Line Encyclopaedia and other published data
Cell line ID Gene Alteration Detected Allele frequency expected Allele frequency observed
Be(2)C TP53 p.C135F YES no data available 100%
Be(2)C MYCN AMPLIFICATION YES not applicable not applicable
CCA KRAS p.Q61L YES no data available 29%
IMR32 ATM p.V2716A YES 59% 59%
IMR32 MYCN AMPLIFICATION YES not applicable not applicable
KELLY ALK p.F1174L YES 39% 32%
KELLY MAP2K1 p.A390T YES 48% 47%
KELLY TP53 p.P177T YES 93% 99%
KELLY MYCN AMPLIFICATION YES not applicable not applicable
LAN1 ALK p.F1174L YES no data available 47%
LAN1 TP53 p.C182* YES no data available 99%
LAN1 MYCN AMPLIFICATION YES not applicable not applicable
LAN5 ALK p.R1275Q YES no data available 50%
LAN5 MYCN AMPLIFICATION YES not applicable not applicable
NBLS NF1 splice_acceptor_variant c.6705-1G>T YES no data available 42%
RD ATM† p.D273N YES 17% 2%
RD NF1 p.E977* YES 56% 59%
RD NRAS p.Q61H YES 68% 61%
RD TP53 p.R248W YES 100% 100%
RH30 CDK4 AMPLIFICATION YES not applicable not applicable
RH41 APC p.M526L YES 60% 59%
RH41 TP53 p.P152fs YES 100% 100%
RMS559 FGFR4 p.V582L YES no data available 76%
SKNAS NRAS p.Q61L YES 45% 46%
SKNAS RB1 p.L477P YES 47% 31%
SKNAS TP53 DEL exons 10,11 YES not applicable not applicable
SKNSH NRAS p.Q61L YES 15% 23%
SKNSH SMARCA4 p.R973T YES 32% 45%
SKNSH CHEK2 p.T410fs YES 59% 44%
SKNSH ALK p.F1174L YES no data available 36%
†ATM mutation in this cell line is subclonal and variation in AF is expected with on-going passages.
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from different quality samples processed in different 
pathology laboratories, demonstrating the value of this 
approach for the development of national and international 
clinical trials in paediatric oncology.
Our data shows that this NGS approach can detect 
structural variants, including amplifications, deletions and 
chromosomal rearrangements. These types of variants are 
not generally detected with commercial amplicon-based 
NGS panels, despite being of critical importance for the 
clinical management and diagnosis of paediatric patients 
(e.g. MYCN amplification in neuroblastoma, EWSR1 in 
Ewing’s sarcoma). Only one out of five chromosomal 
rearrangements involving EWSR1 was not identified by 
the assay which could be due to the lack of coverage 
at the intronic genomic location of the breakpoint. As 
expected, this is one of the limitations of the methodology, 
as capturing intronic regions commonly involved in 
translocations poses challenges associated to the presence 
of repetitive sequence elements. This can be partially 
overcome by including capture baits for the breakpoint 
regions of the most common partner genes involved in the 
translocations.
In summary, we have developed a robust clinical 
test that can detect SNVs, small indels, copy number 
variation and with high reproducibility and repeatability 
in routine clinical FFPE samples from a variety of centres. 
Table 6: Known variants in paediatric FFPE (n=14) and FF (n=14) samples were compared against other platforms 
such as RNA seq, 450k array, Sanger Sequencing and FISH
Genes with alterations detected by other 
methodologies Alteration Tumour type
Total cases 
expected
% of cases 
detected
DDX3X SNV and indel Medulloblastoma 6 100
PTCH1 SNV and indel Medulloblastoma 5 100
TP53 SNV and indel Medulloblastoma 3 100
MYCN SNV Medulloblastoma 2 100
MYCN Amplification
Neuroblastoma (n=3) 
Medulloblastoma 
(n=4)
7 100
CTNNB1 SNV Medulloblastoma 5 100
H3F3A SNV Glioma 3 100
SMARCA4 SNV Medulloblastoma 3 100
BRAF SNV Glioma 2 100
ALK SNV Neuroblastoma 1 100
HIST1H3B SNV Glioma 1 100
AKT1 SNV Medulloblastoma 1 100
ACVR1 SNV Medulloblastoma 1 100
PIK3CA SNV Medulloblastoma 1 100
MLL2 SNV Medulloblastoma 1 100
chr 9q - (PTCH1, TSC1) loss Medulloblastoma 5 100
chr 10- (PTEN, SUFU, FGFR2) loss Medulloblastoma 4 100
chr 6- (HIST1H3B, HIST1H3C, ROS1, ARID1B) loss Medulloblastoma 2 100
chr 9- (CDKN2A/B, PTHC1, TSC1) loss Medulloblastoma 2 100
chr12- (MLL2, CDK4) loss Medulloblastoma 1 100
ATM LOH loss Medulloblastoma 1 100
chr 3p- (CTNNB1, STED2) loss Medulloblastoma 1 100
chr17- (TP53, NF1, HER2, PPM1D) loss Medulloblastoma 1 100
chr17p- (NF1, TP53) loss Medulloblastoma 1 100
Total   60  
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Our approach has been incorporated into a pilot molecular 
profiling study for paediatric patients at the Royal 
Marsden Hospital (London, UK) and this has now been 
extended across the UK as the METEOR programme, an 
interim step towards the UK's more advanced paediatric 
molecular profiling programme, Stratified Medicine-
Paediatrics (SM-Paeds) which is about to be rolled out 
throughout the UK. The NGS panel will form a key part 
of the SM-Paeds programme, which is underpinning 
UK patient eligibility screening for several clinical trials 
including the highly innovative international ITCC basket 
trial, called ESMART (NCT02813135), where patients 
are enrolled according to molecular alterations found in 
their tumours on biopsy at relapse. This is the first time 
that genomic results are incorporated into the patient’s 
record in paediatric cancer in the UK within a clinically 
relevant timeframe of 3-5 weeks from DNA extraction 
to report generation. Our data shows that this NGS assay 
can be an accurate and a practical platform for molecular 
stratification and identification of actionable targets 
required to accelerate personalised medicine clinical trials 
in childhood solid tumours.
MATERIALS AND METHODS
Validation samples
A representative selection of common, poor risk 
paediatric tumours was used for the validation comprising 
132 samples: i) Four cell blends with validated variants 
(Tru-Q1-4 HorizonDiscovery, Cambridge, UK), ii) 15 
paediatric cell lines iii) 83 FFPE clinical samples and iv) 
30 FF clinical samples (Supplementary Table 3).
Local institutional review board approval was 
obtained for the project in addition to separate approvals 
from the contributing tumour banks (The Children’s 
Cancer and Leukaemia Group Tumour Bank and the 
Queensland Children’s Tumour Bank).
Sample preparation
Assessment from haematoxylin and eosin (H&E) 
stained slides was performed by experienced pathologists 
to mark the region of the section containing tumour and to 
estimate neoplastic cell content, defined as the percentage 
of neoplastic cells out of total nucleated cells in the 
marked area. Tumour cellularity, reflecting the density 
of tumour nuclei, was also estimated. Macro-dissection 
of the marked area was performed when a distinct area 
of neoplastic cells from normal cells was observed in a 
large area and the overall tumour content without macro-
dissection would have been <60%. 24 out of the 83 FFPE 
samples underwent macro-dissection to enrich the tumour 
content. DNA from blood and cell lines, FF and FFPE 
samples was extracted using the QIAamp DNA blood 
mini kit, the QIAamp DNA mini kit and the QIAamp DNA 
FFPE tissue kit (Qiagen, Hilden, Germany), respectively. 
For specimens where DNA was extracted at local centres, 
methods are provided in Supplementary Materials. DNA 
was quantified using Qubit dsDNA High Sensitivity 
Assay Kit with the Qubit 2.0 fluorometer, (Invitrogen, 
Carlsbad, CA). Analysis by TapeStation 2200 using the 
genomic DNA ScreenTape assay (Agilent Technologies, 
Santa Clara, CA) was performed to determine the degree 
of fragmentation of genomic DNA prior to library 
preparation. Based on optimization studies, samples 
yielding DNA with median fragment length > 1000 bp 
were processed using 200 ng DNA. Samples with DNA 
< 1000 bp were processed using 400 ng if there was 
sufficient DNA.
Gene panel capture and sequencing
Library preparation was performed using the KAPA 
Hyper and HyperPlus Kit (Kapa Biosystems, Wilmington, 
MA, USA) and SeqCap EZ adapters (Roche, NimbleGen, 
Madison WI, USA), following the manufacturer’s 
protocol, including dual-SPRI size selection of the 
libraries (250-450 bp). In samples prepared using the 
KAPA Hyper Kit (n=39), DNA was sheared with the 
Covaris M220 (Covaris, Woburn, MA) using supplier 
protocols. KAPA HyperPlus employs enzymatic 
fragmentation and was used in 93 samples. Optimization 
of the process indicated that the change from enzymatic 
fragmentation resulted in a substantial improvement in 
library complexity and unique coverage depth compared 
to sonication [44]. Following fragmentation DNA was 
end-repaired, A-tailed and indexed adapters ligated. 
To optimise enrichment and reduce off-target capture, 
pooled, multiplexed, amplified pre-capture libraries (6 to 
10 cycles according to the DNA input) were hybridized 
twice overnight (up to 13 samples per hybridization, 
consecutive days) using 1 μg of the pooled library DNA 
to a custom design of DNA baits complementary to the 
genomic regions of interest (NimbleGen SeqCap EZ 
library, Roche, Madison, WI, USA). A 5 cycle PCR was 
performed between hybridizations to enrich the captured 
product. After hybridisation, unbound capture baits were 
washed away and the remaining hybridised DNA was 
PCR amplified (12 cycles). PCR products were purified 
using AMPure XP beads (Beckman Coulter, Danvers, 
MA, USA) and quantified using the KAPA Quantification 
q-PCR Kit (KAPA Biosystems, Wilmington, MA, USA). 
Sequencing was performed on a MiSeq (Illumina, San 
Diego, CA, USA) with 75 bp paired-end reads and v3 
chemistry according to the manufacturer’s instructions. 
For samples where germline matched control was 
available (n=23), pools from tumour and control DNA 
libraries were multiplexed separately for hybridization 
and combined prior to sequencing at a ratio of 4:1, 
increasing the relative number of reads derived from 
tumour DNA.
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Data analysis
Primary analysis was performed using MiSeq 
Reporter Software (v2.5.1; Illumina), generating 
nucleotide sequences and base quality scores in Fastq 
format. Resulting sequences were aligned against the 
human reference sequence build GRCh37/Hg19 to 
generate binary alignment (BAM) and variant call files 
(vcf). Secondary analysis was performed in-house using 
Molecular Diagnostics Information Management System 
to generate QC, variant annotation, data visualisation and 
a clinical report. In the Molecular Diagnostics Information 
Management System, reads were deduplicated using 
Picard (http://broadinstitute.github.io/picard/), and metrics 
generated for each panel region. Oncotator (v1.5.3.0) 
(https://portals.broadinstitute.org/oncotator) was used to 
annotate point mutations and indels using a minimum 
variant allele frequency (VAF) of 5% and a minimum 
number of 10 variant reads. Manta (https://github.com/
Illumina/manta) was used for the detection of structural 
variants. Variants were annotated for gene names, nature 
of variant (e.g. missense), PolyPhen-2 predictions, and 
cancer-specific annotations from the variant databases 
including COSMIC, Tumorscape, and published MutSig 
results. Copy number variation (CNV) was assessed using 
the ratio of GC-normalized depth of region of interest 
(ROI) in tumour against GC-normalized read depth of ROI 
in either matched germline DNA (when available) or the 
male cell line G147A (Promega, Madison, WI USA). Any 
ratio below 0.65 fold was defined as a potential deletion 
whereas a ratio above 2.4 was flagged as a potential 
amplification. All potential mutations, structural variants 
and CNVs were visualised using IGV and two individuals 
were required to review the mutation report independently. 
Variant calls from samples with previously known SNVs 
and indels were checked manually on IGV.
Cell blends
The four cell blends contained 163 SNVs and 34 
indels common to all four blends (background variants) 
(Supplementary Table 2A). Additionally, there were 61 
SNVs and 17 indels, cancer variants, which were unique 
between blends, introduced at known VAF, and verified 
by ddPCR (Supplementary Table 2B). The four cell blends 
were used to assess overall performance, repeatability, 
intermediate precision, sensitivity and limit of detection. 
Specificity was determined using 87 true negative 
SNV sites (wild type) where another blend harboured a 
mutation at the corresponding position. The cell blends 
were processed and sequenced in two different runs by 
two independent users.
Overall performance
Four cell blends and five FFPE samples were 
used to measure performance across the capture design. 
The log mean depth across the panel was compared 
to the log depth of each region captured for each gene. 
Regions were classified as underperforming if the 
depth was lower than 2 x SD of the mean based on log2 
[log2(ROI)>mean(log2(ROI))-2xSD(log2(ROI))]. GC 
content and mappability scores were compared against 
each region captured by the panel. Quality and coverage 
metrics were calculated across all the samples including i) 
total reads, ii) percentage of reads mapped to the reference 
sequence, iii) percentage of duplicates, iv) percentage of 
bases from unique reads de-duplicated on target, v) mean 
depth of targeted positions and vi) percentage of targeted 
positions with ≥50x, ≥100x and ≥250x coverage.
Limit of detection
To assess the limit of detection and determine a 
reliable cut off for the analysis we used the unique cancer-
specific set of variants from the four cell blends introduced 
at range of VAFs from 4% to 30%, defined by ddPCR.
Precision
Repeatability (or within-run precision) was 
determined by comparing the cell blend background 
variant data across the 4 different samples in the same 
run for variant detection and VAF. Intra-run pairwise 
correlation was calculated for two runs where the cell 
blends were prepared and sequenced by different users 
generating two sets of repeatability data.
Intermediate precision (or between-run precision) 
was determined by comparing the cell blend background 
variant data between two runs for variant detection and 
VAF. Between-run pairwise correlation was calculated 
from two different runs prepared by different users and 
sequenced on different MiSeq instruments.
Sensitivity and specificity
The sensitivity of the panel was determined by 
separately comparing the cell blend background variants 
and the cancer-specific variants introduced at known VAF. 
Specificity was determined using the cell blend cancer-
specific set of data with known variants and known true 
negative sites. Variants were classified according to the 
different ranges of frequencies of the variants present in 
the DNA blends. We also determined Positive-Predictive 
Value and Negative-Predictive Value.
Correlation between NGS targeted panel and 
other methodologies
13 paediatric cancer cell lines were tested 
harbouring a total of 30 known SNVs, deletions and 
amplifications previously identified by the Cancer Cell 
Line Encyclopaedia using Target Enrichment Sequencing 
(Agilent Technologies, Santa Clara, CA) and other 
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published data [45–50]. Furthermore 33 samples (FF=14, 
FFPE=19) had a total of 65 known genetic alterations 
including i) SNVs detected by Sanger Sequencing (H3F3A, 
TP53, CTNNB1, HIST1H3B, ALK, BRAF) [51–53] and 
RNA-Seq ii) copy number changes by FISH (MYCN)
[54] and 450k array and iii) rearrangements by Real-
Time Quantitative PCR involving ESWR1 as previously 
described [55, 56] (Refer to Supplementary Materials).
Fresh frozen vs FFPE samples
15 paired FF and FFPE paediatric samples were 
compared for quality control metrics, coverage and the 
distribution of library inserts sizes between FFPE and FF 
paired samples. In addition, we correlated the VAF of the 
total variants found in the paired samples.
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